News

He needed his medication for multiple sclerosis. He got more paperwork instead.
Rick Blum is meticulous about planning, ordering, and taking the medication he is prescribed to slow the progression of ...
Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%
Roche Holdings AG (OTC:RHHBY) on Tuesday released statistically significant final overall survival (OS) results from the ...
PharmiWeb23m
Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer
Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and chemotherapy121% reduction ...
European Medical Journal22h
Treatment Methods Compared for Overactive Bladder in MS
Discover a study that compared two treatment methods for overactive bladder in patients with multiple sclerosis. Learn more.
Low-dose interleukin-2 added to standard ALS treatment extends patient survival, clinical trial finds
The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard ...